{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:51:36Z","timestamp":1773424296190,"version":"3.50.1"},"reference-count":56,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The therapeutic landscape for chronic lymphocytic leukemia (CLL) has changed dramatically over the past decade as our understanding of the biology of CLL has advanced, allowing the development of oral therapies targeting key drivers of CLL. Currently, inhibitors of Bruton's Tyrosine Kinase and the BH3 mimetic venetoclax are standards of care for both frontline and relapsed\/refractory CLL. Sequencing of available therapies, therefore, has become a major challenge of therapy. In this review, we will focus on the current landscape for the treatment of relapsed\/refractory CLL. We will also discuss important considerations when sequencing these available treatments. The recent advances in this disease are significant steps forward, and raise new questions of how these available drugs should be given as well as how we can continue to improve the treatment of CLL.<\/jats:p>","DOI":"10.1002\/ajh.26683","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T10:54:50Z","timestamp":1663671290000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of relapsed\/refractory Chronic Lymphocytic Leukemia"],"prefix":"10.1002","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine The Ohio State University  Columbus Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29566"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010536"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0964"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198820"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.777837"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049210"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0463"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_2_7_14_1","first-page":"393","article-title":"Three\u2010year follow\u2010up of the Ascend trial: Acalabrutinib versus rituximab plus Idelalisib or Bendamustine in relapsed\/refractory chronic lymphocytic leukemia","volume":"138","author":"Jurczak W","year":"2021","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000640"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17994"},{"key":"e_1_2_7_19_1","article-title":"First interim analysis of alpine study: Results of a phase 3 randomized study of zanubrutinib versus ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","author":"Hillmen P","year":"2021","journal-title":"Haematologica (EHA Abstracts)"},{"issue":"1","key":"e_1_2_7_20_1","first-page":"526","article-title":"Pooled analysis of safety data from monotherapy studies of the BRUTON tyrosine kinase (BTK) inhibitor, ZANUBRUTINIB (BGB\u20103111), in b\u2010cell malignancies","volume":"3","author":"Tam C","year":"2019","journal-title":"Haematologica (EHA Abstracts)"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02727.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506654102"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.03.011"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1119"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012775"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_7_30_1","first-page":"19","article-title":"Five\u2010year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) patients (pts) following fixed\u2010duration Venetoclax\u2010rituximab (VenR) therapy (Tx)","volume":"136","author":"Kater A","year":"2021","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018882555"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.193615"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1237"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01460"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"e_1_2_7_38_1","unstructured":"https:\/\/urldefense.com\/v3\/__https:\/\/www.fda.gov\/media\/157762\/download__;!!AU3bcTlGKuA!A_ODakipEd_Pa\u20105Nr6RLcHTZC25o6vLN\u20102xFDUxJRz7Af2fP6TA0fEKS7gBnpTZGLWWhYUDHUavzDd_IRd0BOQWMYGX8hdrtJF8$."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1313230"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0401"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.8623"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-785998"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-775841"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272500"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e19506"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138725"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3815"},{"issue":"1","key":"e_1_2_7_49_1","article-title":"Outcomes of ibrutinib (Ibr) therapy in Ibr\u2010na\u00efve patients (pts) with chronic lymphocytic leukemia (CLL) progressing after venetoclax (Ven)","volume":"134","author":"Brown JR","year":"2019","journal-title":"Blood"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004782"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134970"},{"key":"e_1_2_7_52_1","first-page":"392","article-title":"Preliminary efficacy and safety of MK\u20101026, a non\u2010covalent inhibitor of wild\u2010type and C481S mutated Bruton tyrosine kinase, in B\u2010cell malignancies: a phase 2 dose expansion study","volume":"138","author":"Woyach J","year":"2021","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011895"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134"},{"key":"e_1_2_7_57_1","first-page":"298","article-title":"Prospective clinical trial of anti\u2010CD19 CAR T cells in combination with Ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate","volume":"132","author":"Gill MSI","year":"2018","journal-title":"Blood (ASH Annual Meeting Abstracts)."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26683","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:26:34Z","timestamp":1692671194000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":56,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/ajh.26683"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26683","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"2022-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}